Korean Journal of Clinical Pharmacy (한국임상약학회지)

Korean College Of Clinical Pharmacy (한국임상약학회)
권호 표지
DOI QR코드

DOI QR Code

Comparison of the Expedited Programs for Innovative Drug Development and Approval among United States, European Union, and Republic of Korea

한국, 미국, 유럽의 혁신적 의약품 개발 및 허가제도 비교 연구

  • Jiyeon Park (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University) ;
  • Hyewon Shin (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University) ;
  • Jangik. I. Lee (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University)
  • 박지연 (서울대학교 약학대학 종합약학연구소) ;
  • 신혜원 (서울대학교 약학대학 종합약학연구소) ;
  • 이장익 (서울대학교 약학대학 종합약학연구소)
  • Received : 2024.01.27
  • Accepted : 2024.03.15
  • Published : 2024.03.31
Download PDF
⟨ Previous Next ⟩

Abstract

Background: The Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Ministry of Food and Drug Safety (MFDS) have been implementing the expedited programs that promote the innovative approval of new medications to be used for serious diseases. The authors comprehensively investigated, analyzed, and compared the regulations and guidelines associated with the expedited programs. Methods: The expedited programs for innovative drug development and approval were searched from the homepages of FDA, EMA and MFDS. The detailed information on the regulations and guidelines associated with the programs was comprehensively extracted from various electronic repositories of each regulatory authority. The information on each program was analyzed, categorized, and compared from the points of benefits, applicability with scientific rationale, application procedure, and maintenance. Results: FDA's programs include Fast Track Designation, Breakthrough Therapy Designation, Priority Review Designation, and Accelerated Approval. EMA's regulation implements PRIority MEdicines (PRIME), Accelerated Assessment, Marketing Authorization under Exceptional Circumstances (MAEC), and Conditional Marketing Authorization (CMA). MFDS has a single Expedited Program. These programs are broadly categorized into those that 1) facilitate early and proactive communication with regulatory authorities, 2) shorten the review time after submitting a marketing application, and 3) temporarily approve a marketing authorization under certain conditions. Conclusion: Each expedited program requires a different level and amount of safety and efficacy evidence to be submitted to each regulatory authority. This article will likely provide the comprehensive information on which program provides scientific and regulatory advantages to be taken for innovative medication development.

Keywords

Acknowledgement

논문을 작성하고 검토하는데 도움을 주신 서울대학교 약학대학의 임하연 연구원님, 정열매 연구원님, 강민서 연구원님, 유승현 연구원님께 감사드립니다.

References

  1. USA, 21 United States Code § 356 - Expedited approval of drugs for serious or life-threatening diseases or conditions. Available from https://www.law.cornell.edu/uscode/text/21/356 Accessed March 22, 2024
  2. APEC Harmonization Center, Drug Approval System of the United States of America. 2016. Available from https://www.mfds.go.kr/brd/m_617/view.do?seq=32337&srchFr=&srchTo=&srchWord=&srchTp=&itm_seq_1=0&itm_seq_2=0&multi_itm_seq=0&company_cd=&company_nm=&page=4 Accessed March 22, 2024
  3. EuroGCT. Expediting marketing authorisation pathways. Available from https://www.eurogct.org/research-pathways/commercialisation/market-access-atmps/expediting-marketing-authorisation-pathways Accessed March 21, 2024
  4. European Medicines Agency. European Medicines Agency Guidance for applicants seeking access to PRIME scheme. Revised on 2023.9.29.Available from https://www.ema.europa.eu/system/files/documents/other/european_medicines_agency_guidance_for_applicants_seeking_access_to_prime_scheme_en_0.pdf Accessed March 22, 2024
  5. Ministry of Food and Drug Safety, Uiyakpum sinsoksimsa bogoseo. 2022.9. Available from https://www.mfds.go.kr/brd/m_218/view.do?seq=33486&srchFr=&srchTo=&srchWord=&srchTp=&itm_seq_1=0&itm_seq_2=0&multi_itm_seq=0&company_cd=&company_nm=&page=1 Accessed March 22, 2024
  6. Pharmaceutical Affairs Act (Act No. 19357) Article 35 (ConditionalPermission), 2022. Available from https://elaw.klri.re.kr/kor_service/jomunPrint.do?hseq=40196&cseq=1050921 Accessed March 22, 2024
  7. Uiyakpum deungui anjeone gwanhan gyuching (chongniryeong No.1835) Article 40(2) (Pummong jogeonbu heoga sincheong deung), 2023. Available from https://www.law.go.kr/%EB%B2%95%EB%A0%B9/%EC%9D%98%EC%95%BD%ED%92%88%EB%93%B1%EC%9D%98%EC%95%88%EC%A0%84%EC%97%90%EA%B4%80%ED%95%9C%EA%B7%9C%EC%B9%99 Accessed March 22, 2024
  8. Ministry of Food and Drug Safety. "[Press notes] Sigyakcheo, jogeonbu heogawa useonsimsa sebu gyujeong deung maryeon," 2021.10.19. Available from https://www.mfds.go.kr/brd/m_99/view.do?seq=45834 Accessed March 22, 2024
  9. Ministry of Food and Drug Safety. Introduction to GIFT. Available from https://mfds.go.kr/wpge/m_1113/de080101l0001.do Accessed October 29, 2023.
  10. Yangmee Shin, Jihong Shon, Hae Young Ahn. "Current Paradigm for Expedited Development of Drugs and Biologics: Breakthrough Therapy Designation," The Korean Society of Food, Drug and Cosmetic Regulatory Sciences 2015;10(2):101-9.
  11. Sylvia Park. "Expedited Drug Development and Approval Programs of the US and EU: Trends and Key Issues," Yakhak Hoeji 2017;61(3):147-57.
  12. Food and Drug Administration. Fast Track. Available from https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/fast-track Accessed October 29, 2023
  13. Food and Drug Administration. Breakthrough Therapy. Available from https://www.fda.gov/patients/fast-track-breatkhrough-therapy-accelerated-approval-priority-review/breakthrough-therapy Accessed October 29, 2023
  14. USA, Title 21 Chapter 1 Subchapter D Part 312 Subpart I - Expanded Access to Investigational Drugs for Treatment Use § 312.300 General, 2009. Available from https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-312/subpart-I Accessed March 22, 2024
  15. Food and Drug Administration. Priority Review. Available from https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/priority-review Accessed October 29, 2023
  16. Food and Drug Administration. Accelerated Approval. Available from https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/accelerated-approval Accessed October 29, 2023
  17. Food and Drug Administartion. Guidance for Industry, Expedited Programs for Serious Conditions-Drugs and Biologics. Available from https://www.fda.gov/media/86377/download Accessed March 21, 2024
  18. Ministry of Food and Drug Safety and Korea Biomedicine Industry Association, Biopharmaceutical Approval ProceduresGuide. 2022.12. Available from https://www.mfds.go.kr/eng/wpge/m_22/de011012l001.do Accessed March 22, 2024
  19. Ministry of Food and Drug Safety Sinsoksimsagwa, haeoe juyogung sinsoksimsa saryejim (minwonin annaeseo). 2021.10. Available from https://www.mfds.go.kr/brd/m_1060/view.do?seq=14924&srchFr=&srchTo=&srchWord=&srchTp=&itm_seq_1=0&itm_seq_2=0&multi_itm_seq=0&company_cd=&company_nm=&page=52 Accessed March 22, 2024
  20. Ministry of Food and Drug Safety Pharmaceuticals and Medical Devices Agency, Uiyakpumui sinsoksimsa jeogyonggijune daehan gaideurain.2021.09. Available from https://www.mfds.go.kr/brd/m_218/view.do?seq=33421&srchFr=&srchTo=&srchWord=&srchTp=&itm_seq_1=0&itm_seq_2=0&multi_itm_seq=0&company_cd=&company_nm=&page=1 Accessed March 22, 2024
  21. Food and Drug Administration, Expedited Programs for Regenerative Medicine Therapies for Serious Conditions: Guidance for Industry.2019.2. Available from https://www.fda.gov/media/120267/download Accessed March 22, 2024
  22. Food and Drug Administration. correspondence documents (for Sotorasib). Available from https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/214665Orig1s000ltr.pdf Accessed March 21, 2024
  23. Food and Drug Administration Center for Drug Evaluation and Research, Integrated Review (for Zokinvy) (Contract No.: 213969Orig1s000). 2020. Available from https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213969Orig1s000IntegratedR.pdf Accessed March 22, 2024
  24. Title 21 Chapter I Subchapter D Part 314 Subpart H - Accelerated Approval of New Drugs for Serious or Life - Threatening Illnesses, 2004. Available from https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-314/subpart-H Accessed March 22, 2024
  25. Deokgyu Lee. "Biogen, Ejai leqembi (lecanemab) FDA Gasokseungin". The Yakup. 2023.01.09. Available from http://m.yakup.com/news/index.html?mode=view&nid=277583 Accessed March 22, 2024
  26. Food and Drug Administration Center for Drug Evaluation and Research, Administrative and correspondence documents (for Lecanemab). 2023. Available from https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/761269Orig1s000ltr.pdf Accessed March 22, 2024
  27. European Medicines Agency. PRIME: priority medicines. Available from https://www.ema.europa.eu/en/human-regulatory-overview/research-development/prime-priority-medicines Accessed November 05, 2023
  28. APEC Harmonization Center. Drug Approval System of European Medicines Agency (EMA); 2020.12. Available from https://www.ema.europa.eu/en/documents/leaflet/european-regulatory-system-medicines_en.pdf Accessed March 22, 2024
  29. European Medicines Agency. Toolbox guidance on scientific elements and regulatory tools to support quality data packages for PRIME and certain marketing authorisation applications targeting an unmet medical need - Scientific guideline. Available from https://www.ema.europa.eu/en/toolbox-guidance-scientific-elements-regulatory-tools-support-quality-data-packages-prime-certain Accessed March 22, 2024
  30. European Medicines Agency, Assessment report: Polivy. 2019.Available from https://www.ema.europa.eu/en/documents/assessment-report/polivy-epar-public-assessment-report_en.pdf Accessed March 22, 2024
  31. European Medicines Agency, List of medicines currently in PRIME scheme. 2023. Available from https://www.ema.europa.eu/en/documents/other/list-medicines-currently-prime-scheme_en.xlsx Accessed March 22, 2024
  32. European Medicines Agency. Acclerated assessment.Available from https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/accelerated-assessment Accessed March 22, 2024
  33. European Medicines Agency. Guideline on the scientific application and the practical arrangements necessary to implement the procedure for accelerated assessment pursuant to Article 14(9) of Regulation (EC) No 726/2004. Available from https://www.ema.europa.eu/en/guideline-scientific-application-and-practical-arrangements-necessary-implement-procedure-accelerated-assessment-pursuant-article-149-regulation-ec-no-726-2004 Accessed March 21, 2024
  34. European Medicines Agency. Pre-authorisation guidance. Available from https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/pre-authorisation-guidance Accessed November 05, 2023
  35. "EMA Validates and Grants Accelerated Assessment for Trastuzumab Deruxtecan for the Treatment of HER2 Positive Metastatic Breast Cancer". Daiichi-Sankyo. 2020.06.06. Available from https://www.daiichisankyo.com/media/press_release/detail/index_3130.html Accessed March 22, 2024
  36. Fabiany da Costa Goncalves Ebru D, Alex Zwiers, A detailed analysis of expedited regulatory review time of marketing authorization applications for new anticancer drugs in the US and EU. Clinical and translational science. 2022;15(8):1959-67.
  37. "Exceptional circumstances," European Medicines Agency, 2023. Available from https://www.ema.europa.eu/en/glossary/exceptional-circumstances Accessed November 05, 2023
  38. EuroGCT. Marketing Authorisation under exceptional circumstances. Available from https://www.eurogct.org/research-pathways/commercialisation/market-access-atmps/expediting-marketing-authorisation-1 Accessed November 05, 2023
  39. European Union. Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use. Available from https://eur-lex.europa.eu/legal-content/en/TXT/?uri=CELEX-%3A32001L0083 Accessed March 21, 2024
  40. European Medicines Agency. Strensiq. Available from https://www.ema.europa.eu/en/medicines/human/EPAR/strensiq Accessed November 05, 2023
  41. European Medicines Agency, Guideline on Procedures for the Granting of a Marketing Authorisation Under Exceptional Circumstances, Pursuant to Article 14 (8) of Regulation (EC) NO 726/2004, 2005.Available from https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-procedures-granting-marketing-authorisation-under-exceptional-circumstances-pursuant-article-14-8-regulation-ec-no-7262004_en.pdf Accessed March 22, 2024
  42. European Medicines Agency. Volume 2B Module 1.2: Administrative information Application form, 2021. Available from https://health.ec.europa.eu/system/files/2021-09/caps-human_en_0.pdf Accessed March 22, 2024
  43. European Medicines Agency. Module 1: Administrative information Application form User guide for the electronic application form for a Marketing Authorisation, 2023. Available from https://www.ema.europa.eu/en/documents/template-form/application-form-user-guide-electronic-application-form- marketing-authorisation_en.pdf Accessed March 22, 2024
  44. Regulation (EC) No 726/2004 of the European Parliament and of the Coundcil, 2004. Available from https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=celex%3A32004R0726 Accessed March 22, 2024
  45. "Conditional marketing authorisation," European Medicines Agency, 2023, Available from https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/conditional-marketing-authorisation Accessed November 05, 2023
  46. European Medicines Agency, Guideline on the scientific application and the practical arrangements necessary to implement Commission Regulation (EC) No 507/2006 on the conditional marketing authorisation for medicinal products for human use falling within the scope of Regulation (EC) No 726/2004. 2016. Available from https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-scientific-application-and-practical-arrangements-necessary-implement-commission-regulation-ec-no-5072006-conditional-marketing-authorisation-medicinal-products-human-use-falling_en.pdf. Accessed March 22, 2024
  47. Decision No 1082/2013/EU of the European Parliament and of the Council, 2013. Available from https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=celex%3A32013D1082 Accessed March 22, 2024
  48. Regulation (EC) No 141/2000 of the European Parliament and of the Council, 2000. Available from https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=celex%3A32000R0141 Accessed March 22, 2024
  49. Commission Regulation (EC) No 507/2006, 2006. Available from https://eur-lex.europa.eu/eli/reg/2006/507/oj Accessed March 22, 2024
  50. "Paxlovid," European Medicines Agency, 2023.Available from https://www.ema.europa.eu/en/medicines/human/EPAR/paxlovid Accessed November 05, 2023
  51. World Health Organization, COVID 19 Public Health Emergency of International Concern (PHEIC) Global research and innovation forum: towards a research roadmap. 2020.Available from https://www.who.int/publications/m/item/covid-19-public-health-emergency-of-international-concern-(pheic)-global-research-and-innovation-forum Accessed March 22, 2024
  52. "Health technology assessment body," European Medicines Agency, 2023. Available from https://www.ema.europa.eu/en/glossary/health-technology-assessment-body Accessed November 05, 2023
  53. "Post-authorisation measures: questions and answers," European Medicines Agency, 2023. Available from https://www.ema.europa.eu/en/human-regulatory/post-authorisation/post-authorisation-measures-questions-answers Accessed November 05, 2023
  54. Act On The Safety of And Support For Advanced Regenerative Medicine And Advanced Biological Products (Act No. 17472). 2023. Available from https://www.law.go.kr/%EB%B2%95%EB%A0%B9/%EC%B2%A8%EB%8B%A8%EC%9E%AC%EC%83%9D%EC%9D%98%EB%A3%8C%EB%B0%8F%EC%B2%A8%EB%8B%A8%EB%B0%94%EC%9D%B4%EC%98%A4%EC%9D%98%EC%95%BD%ED%92%88%EC%95%88%EC%A0%84%EB%B0%8F%EC%A7%80%EC%9B%90%EC%97%90%EA%B4%80%ED%95%9C%EB%B2%95%EB%A5%A0 Accessed March 22, 2024
  55. Cheomdanbaiouiyakpum anjeon min jiwone gwanhan gyuchik. 2020. Available from https://www.law.go.kr/LSW//lsInfoP.do?lsId=013856&ancYnChk=0#0000 Accessed March 22, 2024
  56. APEC Harmonization Center, Drug Approval System of Korea. 2016. Available from https://www.mfds.go.kr/brd/m_617/view.do?seq=35044&srchFr=&srchTo=&srchWord=&srchTp=&itm_seq_1=0&itm_seq_2=0&multi_itm_seq=0&company_cd=&company_nm=&page=3 Accessed March 22, 2024
  57. Uiyakpumui pummokeogasingosimsa gyujeong, 2021-90. 2021. Available from https://www.law.go.kr/LSW//admRulInfoP.do?chrClsCd=010201&admRulSeq=2100000188985 Accessed March 22, 2024
  58. Ministry of Food and Drug Safety, Uiyakpum pummong jogeonbu heoga gwallijichim (minwonin annaeseo). 2022. Available from https://www.mfds.go.kr/brd/m_1060/view.do?seq=15070&srchFr=&srchTo=&srchWord=&srchTp=&itm_seq_1=0&itm_seq_2=0&multi_itm_seq=0&company_cd=&company_nm=&page=1 Accessed March 22, 2024
  59. Rare Disease Managemente Act (Act No. 16410), 2020. Available from https://www.law.go.kr/%EB%B2%95%EB%A0%B9/%ED%9D%AC%EA%B7%80%EC%A7%88%ED%99%98%EA%B4%80%EB%A6%AC%EB%B2%95 Accessed March 22, 2024
  60. Ministry of Food and Drug Safety Sinsoksimsagwa, Uiryojepumui sinsoksimsa jijeongsincheong si goryeosahang (minwonin annaeseo). 2021.5. Available from https://www.mfds.go.kr/brd/m_1060/view.do?seq=14849&srchFr=&srchTo=&srchWord=%EC%9D%98%EB%A3%8C%EA%B8%B0%EA%B8% B0&srchTp=0&itm_seq_1=0&itm_seq_2=0&multi_itm_seq=0&company_cd=&company_nm=&Data_stts_gubun=C9999&page=15 Accessed March 22, 2024
  61. Ministry of Food and Drug Safety Sinsoksimsagwa, Uiryojepumui sinsoksimsa unyeong bangan, 2020. Available from https://www.khidi.or.kr/fileDownload?titleId=428144&fileId=1 Accessed March 22, 2024
  62. Saengmulhakjeokjeje deungui pummokeogatpsimsa gyujeong, 2021-29, 2003.Available from https://www.law.go.kr/%ED%96%89%EC%A0%95%EA%B7%9C%EC%B9%99/%EC%83%9D%EB%AC%BC%ED%95%99%EC%A0%81%EC%A0%9C%EC%A0%9C%EB%93%B1%EC%9D%98%ED%92%88%EB%AA%A9%ED%97%88%EA%B0%80%C2%B7%EC%8B%AC%EC%82%AC%EA%B7%9C%EC%A0%95/(2021-29,20210405) Accessed March 22, 2024
  63. Hanyak(saengyak)jeje deungui pummokeogatpsingoe gwanhan gyujeong, 2016-40, 2011. Available from https://www.law.go.kr/LSW/admRulLsInfoP.do?admRulSeq=2100000221880 Accessed March 22, 2024
  64. The Center for Drug Evaluation and Research, FAST TRACK Designation Requestes Received. 2023.1.24. Available from https://www.fda.gov/about-fda/center-biologics-evaluation-and-research-cber/fast-track-designation-request-performance Accessed March 22, 2024
  65. The Center for Drug Evaluation and Research, CDER Breakthrough Therapy Designation Requests Received by Fiscal Year. 2023. Available from https://www.fda.gov/media/95292/download Accessed March 22, 2024
  66. European Medicines Agency, PRIME: Analysis of the first 5 years' experience. 2022. Available from https://www.ema.europa.eu/en/documents/report/prime-analysis-first-5-years-experience_en.pdf Accessed March 22, 2024
  67. Food and Drug Administration, Avastin (bevacizumab) Information. 2018. Available from https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/avastin-bevacizumab-information Accessed March 22, 2024
  68. Food and Drug Administration, Withdrawn | Cancer Accelerated Approvals; 2023. Available from https://www.fda.gov/drugs/resources-information-approved-drugs/withdrawn-cancer-accelerated-approvals Accessed March 22, 2024
  69. The Center for Drug Evaluation and Research, CDER Drug and Biologic Accelerated Approvals Based on a Surrogate Endpoint As of September 30, 2023. Available from https://www.fda.gov/media/151146/download?attachment Accessed March 22, 2024
  70. The Center for Biologics Evaluation and Research, CBER Drug and Biologic Accelerated Approvals Based on a Surrogate Endpoint As of December 31, 2022. Available from https://www.fda.gov/media/165428/download?attachment Accessed March 22, 2024
  71. European Medicines Agency, Table of all EPARs for human and veterinary medicines. 2023. Available from https://www.ema.europa.eu/en/medicines/download-medicine-data Accessed March 22, 2024
  72. European Medicines Agency, Human Medicines Highlights 2022. Available from https://www.ema.europa.eu/system/files/documents/report/human_medicines_highlights_2022_update_3_may_en.pdf Accessed March 22, 2024